

Timothy D Gilligan

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8286442/timothy-d-gilligan-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

124
papers

2,675
citations

26
h-index

50
g-index

136
ext. papers

3,283
ext. citations

3.5
avg, IF

5.02
L-index

#	Paper	IF	Citations
124	Implications of the United States Preventive Services Task Force Recommendations on Prostate Cancer Stage Migration. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, e12-e16	3.3	0
123	Blood Myeloid-Derived Suppressor Cells Correlate with Neutrophil-to-Lymphocyte Ratio and Overall Survival in Metastatic Urothelial Carcinoma. <i>Targeted Oncology</i> , 2020 , 15, 211-220	5	9
122	Myeloid-Derived Suppressor Cells in Nonmetastatic Urothelial Carcinoma of Bladder Is Associated With Pathologic Complete Response and Overall Survival. <i>Clinical Genitourinary Cancer</i> , 2020 , 18, 500-508	3.3	4
121	ASCO Quality Training Program: A Five-Year Review. <i>JCO Oncology Practice</i> , 2020 , 16, e1243-e1248	2.3	1
120	Clinical Activity of Ipilimumab Plus Nivolumab in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2020 , 18, 429-435	3.3	20
119	Identifying Prostate Surface Antigen Patterns of Change in Patients with Metastatic Hormone Sensitive Prostate Cancer Treated with Abiraterone and Prednisone. <i>Targeted Oncology</i> , 2020 , 15, 477-483	5.3	2
118	Individualised axitinib regimen for patients with metastatic renal cell carcinoma after treatment with checkpoint inhibitors: a multicentre, single-arm, phase 2 study. <i>Lancet Oncology</i> , 2019 , 20, 1386-1394	21.7	50
117	High-dose chemotherapy and autologous transplantation for testicular germ cell tumors. <i>Advances in Cell and Gene Therapy</i> , 2019 , 2, e47	1.2	1
116	A phase II trial of intermittent nivolumab in patients with metastatic renal cell carcinoma (mRCC) who have received prior anti-angiogenic therapy 2019 , 7, 127		13
115	Personalizing Medicine. <i>Journal of Clinical Oncology</i> , 2019 , 37, 165-166	2.2	
114	Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 1529-1554	7.3	62
113	Challenges With the 8th Edition of the AJCC Cancer Staging Manual for Breast, Testicular, and Head and Neck Cancers. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 560-564	7.3	5
112	Implications of the United States Preventive Services Task Force (USPSTF) recommendations on prostate cancer (PCa) stage migration.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 5071-5071	2.2	
111	Diagnosis and Treatment of Early Stage Testicular Cancer: AUA Guideline. <i>Journal of Urology</i> , 2019 , 202, 272-281	2.5	70
110	Ethical Issues in the Cardiac Intensive Care Unit 2019 , 11-26.e3		0
109	Transcriptomic and Protein Analysis of Small-cell Bladder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target. <i>Clinical Cancer Research</i> , 2019 , 25, 210-221	12.9	30
108	Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials: Focus on Efficacy, Safety, and Response to Subsequent Therapies. <i>Targeted Oncology</i> , 2018 , 13, 353-361	5	11

107	Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 405-412	2.8	30
106	Feasibility of Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer Patients With Diminished Renal Function. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e879-e892	3.3	16
105	Drug Holiday in Metastatic Renal-Cell Carcinoma Patients Treated With Vascular Endothelial Growth Factor Receptor Inhibitors. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e663-e667	3.3	11
104	Prognostic Factors and Risk Stratification in Invasive Upper Tract Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e751-e760	3.3	9
103	Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma 2018 , 6, 9		105
102	The association between facility case volume and overall survival in patients with metastatic renal cell carcinoma in the targeted therapy era. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 470.e19-470.e29	2.8	4
101	Effect of Switching Systemic Treatment After Stereotactic Radiosurgery for Oligoprogressive, Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, 413-419.e1	3.3	13
100	Treatment selection for men with metastatic prostate cancer who progress on upfront chemo-hormonal therapy. <i>Prostate</i> , 2018 , 78, 1035-1041	4.2	7
99	Clinicopathologic factors, treatment patterns, and outcomes in micropapillary urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 439-439	2.2	3
98	Clinical outcome of patients (Pts) with metastatic renal cell carcinoma (mRCC) progressing on front-line immune-oncology based combination (IO-COMBO) regimens.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 613-613	2.2	6
97	Atezolizumab (atezo) and subsequent therapies in patients (Pts) with metastatic urothelial carcinoma (mUC) outside clinical trials.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 432-432	2.2	
96	Impact of neoadjuvant chemotherapy on pathologic outcomes in patients with upper tract urothelial carcinoma undergoing extirpative surgery.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 457-457	2.2	
95	The association between HSD3B1 genotype and steroid metabolism in normal and prostate cancer (PCa) tissue.. <i>Journal of Clinical Oncology</i> , 2018 , 36, TPS155-TPS155	2.2	
94	Response to platinum-based therapy (PBT) and immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (mUC) patients (pts) with genomic alterations (GA) in homologous recombination repair (HRR) genes.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 447-447	2.2	
93	Treatment patterns for metastatic hormone-sensitive prostate cancer (mHSPC) progressing after up-front docetaxel in combination with androgen deprivation therapy (D-ADT).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 305-305	2.2	
92	Immunological correlates of response to immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (mUC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 454-454	2.2	
91	Cisplatin-based neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC) in patients (pts) with impaired renal function.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 446-446	2.2	
90	The impact of switching systemic treatment after radiosurgery (SBRT) for oligo-progressive, metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 599-599	2.2	

89	Serial changes in PD1/PDL1 expression in metastatic urothelial carcinoma (mUC) patients (pts) treated with immune checkpoint blockade (CPB).. <i>Journal of Clinical Oncology</i> , 2018 , 36, 109-109	2.2	
88	Outcomes and patterns of disease progression in metastatic renal cell carcinoma patients treated with nivolumab.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 654-654	2.2	0
87	Patient Characteristics, Treatment Patterns and Prognostic Factors in Squamous Cell Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e437-e442	3.3	12
86	A Pathologic Fascination With Humanity. <i>Journal of Clinical Oncology</i> , 2018 , 36, 425-426	2.2	1
85	Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline Summary. <i>Journal of Oncology Practice</i> , 2018 , 14, 42-46	3.1	26
84	Patient-Clinician Communication Is a Joint Creation: Working Together Toward Well-Being. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018 , 38, 532-539	7.1	6
83	Evaluation of T cell infiltration in matched biopsy and nephrectomy samples in renal cell carcinoma. <i>Medicine (United States)</i> , 2018 , 97, e12344	1.8	4
82	Immunological Correlates of Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma. <i>Targeted Oncology</i> , 2018 , 13, 599-609	5	12
81	Testicular cancer. <i>Nature Reviews Disease Primers</i> , 2018 , 4, 29	51.1	164
80	Patterns, predictors and subsequent outcomes of disease progression in metastatic renal cell carcinoma patients treated with nivolumab 2018 , 6, 107		36
79	Impact of Neoadjuvant Chemotherapy on Pathologic Response in Patients With Upper Tract Urothelial Carcinoma Undergoing Extirpative Surgery. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, e1237-e1242	3.3	24
78	The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2018 , 119, 160-163	8.7	25
77	Chemotherapy Is the Preferred Treatment for Seminomas Relapsing After First-line Chemotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 99, 511	4	
76	Patient-Clinician Communication: American Society of Clinical Oncology Consensus Guideline. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3618-3632	2.2	227
75	Talking About Death. <i>Journal of Oncology Practice</i> , 2017 , 13, 672-674	3.1	1
74	Clinical Effect of Dose Escalation After Disease Progression in Patients With Metastatic Renal Cell Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, e275-e280	3.3	16
73	Nivolumab treatment for patients with non-clear cell renal cell carcinoma: A multicenter retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4586-4586	2.2	10
72	Real-world experience with atezolizumab (atezo) in advanced urothelial cancer (UC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, e16031-e16031	2.2	0

71	T cell infiltration (TCI) in matched renal biopsy (bx) and nephrectomy (nx) samples in renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 4587-4587	2.2	
70	Decision Making in a Data-Poor Environment: Management of Brain Metastases From Testicular and Extragenital Germ Cell Tumors. <i>Journal of Clinical Oncology</i> , 2016 , 34, 303-6	2.2	6
69	Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1945-52	2.2	150
68	Chemotherapy and Fertility. <i>Current Clinical Urology</i> , 2016 , 97-107		1
67	ReCAP: Feasibility and Effectiveness of a Pilot Program to Facilitate Quality Improvement Learning in Oncology: Experience of the American Society of Clinical Oncology Quality Training Program. <i>Journal of Oncology Practice</i> , 2016 , 12, 177; e215-23	3.1	3
66	What we really talk about when we talk about food. <i>Journal of Clinical Oncology</i> , 2015 , 33, 665-6	2.2	
65	Quality of life among testis cancer survivors. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 413-9	2.8	10
64	Personalizing, not patronizing: the case for patient autonomy by unbiased presentation of management options in stage I testicular cancer. <i>Annals of Oncology</i> , 2015 , 26, 833-838	10.3	36
63	A Phase II Study of Pazopanib in Patients with Localized Renal Cell Carcinoma to Optimize Preservation of Renal Parenchyma. <i>Journal of Urology</i> , 2015 , 194, 297-303	2.5	61
62	Health and quality of life among survivors of testis cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 390-1	2.8	2
61	Clinical Implications of the Different Histologic Subtypes of Testicular Tumors 2015 , 483-489		
60	Clinical effect of TKI dose-escalation after disease progression in patients with metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 4562-4562	2.2	
59	The REDE Model of Healthcare Communication: Optimizing Relationship as a Therapeutic Agent. <i>Journal of Patient Experience</i> , 2014 , 1, 8-13	1.3	43
58	The ASCO Quality Training Program: designing and implementing a medical specialty society-based quality improvement training program. <i>Journal of Oncology Practice</i> , 2014 , 10, 203-5	3.1	12
57	Germ Cell Tumors 2014 , 645-650		
56	High-priority topics for cancer quality measure development: results of the 2012 American Society of Clinical Oncology Collaborative Cancer Measure Summit. <i>Journal of Oncology Practice</i> , 2014 , 10, e160-6 ¹	3.1	14
55	Outcomes of treatment cessation in select metastatic renal cell carcinoma (mRCC) patients.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4521-4521	2.2	3
54	Clinical activity of abiraterone acetate in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 99-99	2.2	1

53	A phase II study of pazopanib (P) in patients (Pts) with localized renal cell carcinoma (RCC) to enable partial nephrectomy (PN).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 4522-4522	2.2	
52	The Morbidity and Mortality Conference (MMC) in Oncology: A patient safety and root cause analysis (RCA)-driven approach at the Cleveland Clinic Taussig Cancer Institute (TCI).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 191-191	2.2	1
51	A 45-year-old with neuroendocrine carcinoma of the prostate. <i>Urology</i> , 2013 , 81, 714-6	1.6	2
50	In reply. <i>Oncologist</i> , 2013 , 18, e2	5.7	
49	Immune cell repertoire in patients with indolent metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 429-429	2.2	
48	Implementing a comprehensive physician-communication-skills improvement initiative: The Cleveland Clinic experience.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 186-186	2.2	
47	Cessation of vascular endothelial growth factor-targeted therapy in patients with metastatic renal cell carcinoma: feasibility and clinical outcome. <i>Cancer</i> , 2012 , 118, 3277-82	6.4	17
46	Is there such a thing as a cancer treatment that isn't worth its cost?. <i>Oncologist</i> , 2012 , 17, 3-4	5.7	4
45	If I paint a rosy picture, will you promise not to cry?. <i>Journal of Clinical Oncology</i> , 2012 , 30, 3421-3	2.2	1
44	Neoplasms of the Testis 2012 , 837-870.e9		15
43	Testicular cancer survivorship. <i>Hematology/Oncology Clinics of North America</i> , 2011 , 25, 627-39, x	3.1	14
42	Management of low-stage nonseminomatous germ cell tumors of testis: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009. <i>Urology</i> , 2011 , 78, S444-55	1.6	13
41	Management of localized seminoma, stage I-II: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009. <i>Urology</i> , 2011 , 78, S435-43	1.6	21
40	To better manage cancer symptoms. <i>Cleveland Clinic Journal of Medicine</i> , 2011 , 78, 24	2.8	
39	ASCO Clinical Practice Guideline on Uses of Serum Tumor Markers in Adult Males With Germ Cell Tumors. <i>Journal of Oncology Practice</i> , 2010 , 6, 199-202	3.1	18
38	Defining the optimal treatment for clinical stage I nonseminomatous germ cell testicular cancer using decision analysis. <i>Journal of Clinical Oncology</i> , 2010 , 28, 119-25	2.2	25
37	A church-based intervention to promote informed decision making for prostate cancer screening among African American men. <i>Journal of the National Medical Association</i> , 2010 , 102, 164-71	2.3	61
36	American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors. <i>Journal of Clinical Oncology</i> , 2010 , 28, 3388-404	2.2	171

35	Sorafenib in patients with metastatic renal cell carcinoma refractory to either sunitinib or bevacizumab. <i>Cancer</i> , 2010 , 116, 5383-90	6.4	59
34	Management of poor-prognosis testicular germ cell tumors. <i>Indian Journal of Urology</i> , 2010 , 26, 108-14	0.8	6
33	Ethical Issues of Care in the Cardiac Intensive Care Unit 2010 , 9-24		1
32	Controversies in the management of early-stage germ cell tumors. <i>Current Oncology Reports</i> , 2009 , 11, 235-43	6.3	3
31	Adjuvant Chemotherapy in Bladder Cancer: A Good Concept But Where's the Proof? 2009 , 239-245		1
30	A case of spermatic cord teratoma in low-stage testicular cancer managed by surveillance. <i>Nature Reviews Urology</i> , 2008 , 5, 220-3		
29	Rates of biochemical remission remain higher in black men compared to white men after radical prostatectomy despite similar trends in prostate specific antigen induced stage migration. <i>Journal of Urology</i> , 2007 , 178, 1271-6	2.5	10
28	Pathological evidence of necrosis in recurrent renal mass following treatment with sunitinib. <i>International Journal of Urology</i> , 2007 , 14, 1095-7; discussion 1097	2.3	42
27	African-American men's perceptions about prostate cancer: implications for designing educational interventions. <i>Social Science and Medicine</i> , 2007 , 64, 2189-200	5.1	96
26	The atypical urothelial cancer patient: management of bladder cancers of non-transitional cell histology and cancers of the ureters and renal pelvis. <i>Seminars in Oncology</i> , 2007 , 34, 145-53	5.5	14
25	Management of clinical stage I nonseminomatous germ cell testicular cancer. <i>Urologic Clinics of North America</i> , 2007 , 34, 137-48; abstract viii	2.9	25
24	Testis cancer: rare, but curable with prompt referral. <i>Cleveland Clinic Journal of Medicine</i> , 2007 , 74, 817-25		4
23	Carboplatin for stage I seminoma. <i>Journal of Clinical Oncology</i> , 2006 , 24, 2971-2; author reply e32-3	2.2	4
22	Republication of SEMPET trial data?. <i>European Journal of Radiology</i> , 2006 , 58, 317; author reply 318	4.7	
21	Testis Cancer 2006 , 851-880		
20	Intertubular growth in pure seminomas: associations with poor prognostic parameters. <i>Human Pathology</i> , 2005 , 36, 640-5	3.7	20
19	Social disparities and prostate cancer: mapping the gaps in our knowledge. <i>Cancer Causes and Control</i> , 2005 , 16, 45-53	2.8	64
18	Changing management of clinical low-stage testicular cancer. <i>Scientific World Journal, The</i> , 2005 , 5, 852-67		

17	Retroperitoneal lymph node dissection versus chemotherapy for stage I testicular nonseminomas. <i>Annals of Oncology</i> , 2005 , 16, 172-3	10.3	
16	Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. <i>Clinical Cancer Research</i> , 2005 , 11, 4430-6	12.9	127
15	Absence of a correlation of androgen receptor gene CAG repeat length and prostate cancer risk in an African-American population. <i>Clinical Prostate Cancer</i> , 2004 , 3, 98-103		27
14	Impact of race on survival in men with metastatic hormone-refractory prostate cancer. <i>Urology</i> , 2004 , 64, 212-7	1.6	25
13	Racial differences in screening for prostate cancer in the elderly. <i>Archives of Internal Medicine</i> , 2004 , 164, 1858-64		78
12	When do we stop talking about curative care?. <i>Journal of Palliative Medicine</i> , 2003 , 6, 657-60	2.2	1
11	Chemotherapy for prostate cancer. <i>Urology</i> , 2002 , 60, 94-100; discussion 100	1.6	99
10	Bicalutamide Monotherapy Compared with Castration in Patients with Nonmetastatic Locally Advanced Prostate Cancer: 6.3 Years of Follow-up. <i>Prostate Journal</i> , 2001 , 3, 42-43		4
9	Overall Survival after Prostate-Specific-Antigen-Detected Recurrence Following Conformal Radiation Therapy.. <i>Prostate Journal</i> , 2001 , 3, 43-44		
8	Prospective Trial of the Herbal Supplement PC-SPEC in Patients with Progressive Prostate Cancer.. <i>Prostate Journal</i> , 2001 , 3, 44-45		
7	Biochemical Outcome Following External Beam Radiation Therapy With or Without Androgen Suppression Therapy for Clinically Localized Prostate Cancer.. <i>Prostate Journal</i> , 2001 , 3, 45-46		
6	Ethical decision-making in critical care in Hong Kong. <i>Critical Care Medicine</i> , 1998 , 26, 447-51	1.4	62
5	Whose death is it, anyway?. <i>Annals of Internal Medicine</i> , 1996 , 125, 137-41	8	20
4	Obstetric complications in pulmonary and critical care medicine. <i>Chest</i> , 1996 , 110, 791-809	5.3	36
3	End-of-life discussions with patients. Timing and truth-telling. <i>Chest</i> , 1996 , 109, 11-2	5.3	12
2	Withdrawing life support: extubation and prolonged terminal weans are inappropriate. <i>Critical Care Medicine</i> , 1996 , 24, 352-3	1.4	38
1	Rapid withdrawal of support. <i>Chest</i> , 1995 , 108, 1407-8	5.3	22